Menadione has been known as an oxidative damage-inducing agent and has been studied in gastric cancer cell lines, where it resulted in proteasome-mediated degradation of Cyclin B1 and CDK1 without reducing the mRNA levels of these genes, with an overall cell cycle arrest in the G2-M phase [202]. This evidence concerns the gene CDK1 and gastric cancer.